Stockholders Sue United Therapeutics for Phony Stock Options Tied to Touting Stock

United Therapeutics announced that on January 28, 2010, the Compensation Committee of the Board of Directors of United Therapeutics Corporationapproved the 2010 salaries and cash and long-term incentive bonus target opportunities for theCompany's 16 executive officers.Dr. Martine Rothblatt's annual base salary was increased 11% from $810,000 to$900,000. Dr. Rothblatt's annual cash incentive bonus target opportunity was increased 16% from $775,000 to$900,000.  Dr. Rothblatt may be entitled to receive a stock option grant on December 31, 2010, inaccordance with the formula set forth in her employment agreement, which takesinto account the rise, if any, in the Company's market capitalization from December2009 to December 2010. Any sort of compensation package which is based on the stock price of a company rather than its actual earnings could be in violation of SEC and public securities disclosure laws!Dr. Roger Jeffs' annual base salary was increased 3% from $710,000 to $730,000.  In addition, Dr. Jeffs' annual cash incentivebonus target opportunity was increased 8% from $510,000 to $550,000, and hisannual long-term incentive bonus target opportunity remained unchanged at175,000 Share Tracking Awards ("Awards") under the Company's Share Tracking Awards Plan.Mr. Paul Mahon's annual base salary was increased 3% from $615,000 to $635,000.  In addition, Mr. Mahon's annual cash incentive bonus target opportunity wasincreased 9% from $345,000 to $375,000, and his annual long-term incentive bonus target opportunity remained unchanged at $125,000.Mr. John Ferrari's annual base salary was increased 10% from $400,000 to $440,000.  In addition, Mr. Ferrari's annual cashincentive bonus target opportunity was increased 19% from $210,000 to $250,000,and his annual long-term incentive bonus target opportunity remained unchangedat 125,000 Awards.An investigation has uncovered a widespread pattern of abuse in option grants to the CEO and members of the Board and management of United Therapeutics Corporation. The options abuse at United Therapeutics has been costly to shareholders. As aresult of the improper option grants, Awards grants and repricing of options and Awards, the Company was required to take a charge against earnings totaling $55.3million. This charge was partly responsible for the Company reporting a $42.8 millionnet loss for fiscal 2008 as opposed to the reported net income of $19.8 millionfor the prior year.If you own shares in United Therapeutics from at least prior to December 2007 andwould like to participate in challenging the options abuse, please send (via emailor fax to 212.363.7171) a copy of a signed Retainer Agreement[http://r20.rs6.net/tn.jsp?et=1103049436251&s=957&e=001x1-0d0mjeAb8gJV5uI0gXjWxQe
XZj2EDQxSd74gPXVEBd_tqTDMBJ0KO6whLWgVoZsMzpHiFh1teYhuqdwOB8beVtNOBGlIV5VtLWM90Gs
hV9-BzCTEZAeKx2xBlx1gbWDs1t9V7o02Cq32u2B0dzg==]anda recent accountstatement that shows your ownership of United Therapeutics shares prior to December2007. (Please feel free to redact any personalinformation in any documents you send.) If you would like
wish to obtain additional information, please contactus at the number listed below or visit http://www.zlk.com/uthr1.html.Sources:

Levi & Korsinsky LLP | 30 Broad Street | 15th Floor | New York, New York 10004Tel. 212.363.7500 | Fax 212.363.7171 | www.zlk.com[http://r20.rs6.net/tn.jsp?et=1103049436251&s=957&e=001x1-0d0mjeAYGTfUL__hwXuLTY-
Cin6ZmPWb6pthIshqHzBw0HEyDrlFsUmBDDAncJm6Wuj5C5w6SMascx5GhJ8MQPg4VHFDy3-CE4mSIKw
g=]